Allogene Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Allogene Therapeutics, Inc. filed a current report on October 25, 2018, with the report signed on October 29, 2018. The filing reports entry into a material lease agreement and does not provide quarterly or annual financial results.
Material Agreement and Financial Terms
- On October 25, 2018, the company entered into a lease with HCP, Inc. for approximately 14,943 square feet of office and laboratory space in South San Francisco, California.
- The lease term is 10 years and four months, commencing November 1, 2018.
- Monthly rent is $37,734 for the first seven months, reflecting abatement of base rent on half of the rentable space.
- Monthly rent increases to $75,462 for months eight through 12, stated as $5.05 per square foot.
- Thereafter, the price per square foot increases approximately 3.5% annually.
- Subject to specified conditions, the company may extend the lease for an additional seven years.
Changes, Outlook, Risks, and Unusual Items
The lease adds a long-term facility commitment and related occupancy costs. The filing does not provide the total minimum lease payments, accounting treatment, security deposit, termination provisions, or other detailed contingencies. The full lease was to be filed as an exhibit in a subsequent SEC filing.
Key Facts to Verify
- Review the subsequent filing containing the complete lease agreement.
- Verify the total contractual rent obligation, annual escalations, and any tenant-improvement or other related costs.
- Confirm the conditions and economics of the seven-year extension option.
- Assess the effect of the new facility commitment on future cash requirements and operating expenses.